Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆

ESMO Open(2024)10.1016/j.esmoop.2024.103973Source: DataRank Database

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆ is a research paper published in ESMO Open (2024). On theSindex it has a DataRank of 0.385. It has been cited 12 times.

N/A

0.385DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.26)OA: goldTopics (64)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.385

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (20)

Danielle Brandes Zakon ORCID,Qingchun Jin ORCID,Ava Strahan ORCID,Melissa Grimm ORCID,Melissa E. Hughes ORCID

Live enrichment

PubMed:39500139 PMC:PMC11570474 OpenAlex:https://openalex.org/W4404042386

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

National Institutes of Health

Grant: 5P50CA168504-03

Overcoming Resistance to Standard HER2-Directed Therapies for Breast Cancer

FWCI

2.26

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.esmoopen.com/article/S2059702924017435/pdf

publisherhttp://www.esmoopen.com/article/S2059702924017435/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2059702924017435?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2059702924017435?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.esmoop.2024.103973

Fields of Study

Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchBreast Lesions and Carcinomas03 medical and health sciences0302 clinical medicineHumansTriple Negative Breast NeoplasmsFemaleNeoadjuvant TherapyMiddle AgedErb-b2 Receptor Tyrosine KinasesAdultAgedAged, 80 and overYoung AdultNeoplasm StagingRetrospective StudiesTreatment OutcomeImmunohistochemistry

MeSH Terms

AdultAgedAged, 80 and overFemaleHumansImmunohistochemistryMiddle AgedNeoplasm StagingRetrospective StudiesTreatment OutcomeErb-b2 Receptor Tyrosine KinasesReceptor, ErbB-2Neoadjuvant TherapyYoung AdultTriple Negative Breast Neoplasms

Keywords

Stage (stratigraphy)OncologyBreast cancerMedicineInternal medicineChemotherapyTriple-negative breast cancerTriple negativeNeoadjuvant therapyCancerBiologyPCRSurvivalEarly stageTnbcHer2 LowAdultAged, 80 and overTriple Negative Breast NeoplasmsMiddle AgedErb-b2 Receptor Tyrosine KinasesImmunohistochemistryYoung AdultTreatment OutcomeHumansOriginal ArticleFemaleAgedNeoplasm StagingRetrospective Studies

Sustainable Development Goals

SDG 0: Good health and well-being

Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status☆

FAIR Checklist

DataRank Breakdown

Authors (20)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)